Cryo-Cell International

ZCY

The current Cryo-Cell International (ZCY) market capitalization is approximately €22.50M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Cryo-Cell International's market cap fluctuates with changes in its share price and share count. Last updated: March 7, 2026 at 8:02 PM Eastern Time

In the most recently reported quarter, Cryo-Cell International (ZCY) generated $7.84M in revenue, representing a -2.26% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately $7.73M, implying an expected -2.95% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: April 3, 2026 at 11:26 AM Eastern Time

In the most recently reported fiscal year, Cryo-Cell International (ZCY) generated net income of $-2.43M, compared with $402.10K in the prior fiscal year, representing a -704.18% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of $518.00K. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: April 3, 2026 at 11:26 AM Eastern Time

According to its latest quarterly filing, Cryo-Cell International (ZCY) reported EBITDA of $618.78K, representing a +124.76% year over year change. For the upcoming quarter, analyst consensus currently expects EBITDA of $763.00K, reflecting assumptions around revenue trends, operating costs, scale efficiencies, and margin dynamics. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: April 3, 2026 at 11:26 AM Eastern Time

Based on the latest available data, Cryo-Cell International (ZCY) is currently trading at a last twelve months (LTM) P/E ratio of -13.51x. Looking forward, the stock trades at a next twelve months (NTM) P/E ratio of 40.44x, based on consensus earnings estimates. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: April 3, 2026 at 11:26 AM Eastern Time

Cryo-Cell International (ZCY) is currently scheduled to report its next earnings results on April 12, 2026. Earnings dates are subject to change and may be updated by the company with limited notice. Investors typically monitor upcoming earnings releases closely, as they can result in increased volatility depending on reported results, forward guidance, and management commentary. Last updated: March 7, 2026 at 8:02 PM Eastern Time

In the most recently reported quarter, Cryo-Cell International (ZCY) revenue was $7.84M, compared with analyst consensus expectations of $7.70M, representing a +1.86% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were $-0.47, compared with consensus estimates of $-0.09, resulting in an -417.33% EPS surprise. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: April 3, 2026 at 11:26 AM Eastern Time

Based on the latest available analyst coverage, Cryo-Cell International (ZCY) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: April 3, 2026 at 11:26 AM Eastern Time

Like other publicly traded stocks, Cryo-Cell International (ZCY) shares are bought and sold on stock exchanges such as NYSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Cryo-Cell International (ZCY) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add ZCY to your watchlist.

Cryo-Cell International trades under the ticker symbol ZCY on the NYSE stock exchange. The ticker ZCY is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Cryo-Cell International (ZCY) employs approximately 84 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: March 7, 2026 at 8:02 PM Eastern Time

Cryo-Cell International (ZCY) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Cryo-Cell International (ZCY) stock peers based on overlapping products, services, and competitive dynamics:Labcorp Holdings (LH)StemCell Institute (7096)MEDIPOST (A078160)FamiCord (V3V)Cordlife Group (P8A)Medeze Group Public (MEDEZE)Safe Fertility Group Public (SAFE) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Cryo-Cell International.